Insulin-like growth factor-1 in myocardial ischemia-reperfusion injury: A review
Zhenrong Yan,Ziyang Xing,Tingyun Xue,Jiaye Zhao,Guangmei Li,Liwenjing Xu,Qiyu Sun
DOI: https://doi.org/10.1097/md.0000000000037279
IF: 1.6
2024-03-13
Medicine
Abstract:In developed countries, ischemic heart disease (IHD) stands as a primary cause of mortality and disability, followed by cerebrovascular disease. [ 1 ] Moreover, cardiovascular diseases, including myocardial infarction, heart failure, vascular dementia, hypertension, and its complications, rank as the leading causes of death in China. Heart failure results from various forms of cardiovascular diseases, and in 2013, IHD replaced stroke as the leading cause of death. [ 2 ] The increasing morbidity and mortality rates associated with IHD pose a serious threat to human health. Recanalization and reperfusion of obstructed vessels through thrombolytic medication, coronary bypass operation, and percutaneous coronary intervention are recognized as the most efficient therapeutic strategies for the treatment of myocardial ischemia. [ 3 ] There is evidence that in myocardial ischemia/reperfusion, both ischemia and reperfusion cause damage to cardiomyocytes. [ 4 , 5 ] Therefore, myocardial reperfusion may exacerbate ischemic cardiomyocyte death in patients with myocardial infarction, leading to myocardial ischemia-reperfusion injury (MIRI). [ 5 , 6 ] The pathophysiology of MIRI involves calcium overload, oxidative stress, excessive reactive oxygen species (ROS) production, mitochondrial damage, inflammatory response, cell death, and signaling pathways associated with cell survival. [ 7 ] Hence, it is important to develop treatments that target the molecular mechanisms underlying the development of MIRI for the therapy of IHD and protection against MIRI.
medicine, general & internal